BALAXI
BALAXI PHARMACEUTICALS LIMITED (BALAXI) Stock Analysis
BALAXI PHARMACEUTICALS LIMITED is an Indian pharmaceutical company manufacturing formulations and healthcare products. It markets medicines in domestic and international generic markets. The company operates manufacturing facilities in India. It is a listed small-cap pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹23.40
+6.74% 1W | -41.80% 52W
Market Cap
129 CR
P/E Ratio
52.1
52W High
₹41
52W Low
₹15.2
Div. Yield
0%
Beta
0.8
50 DMA
₹22.3
200 DMA
₹23
Profit Margin
0.9%
Inst. Own.
0%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 65.96 | 54.72 | 60.79 | 59.83 | 65.62 | 77.38 | 73.29 | 76.27 | 70.74 | 56.18 | 72.54 | 70.71 | 80.68 |
| YoY Sales growth | -20.32% | -36.65% | -29.79% | -25.84% | -0.52% | +41.41% | +20.56% | +27.48% | +7.80% | -27.40% | -1.02% | -7.29% | +14.05% |
| Expenses | 57.12 | 43.96 | 47.14 | 46.36 | 55.53 | 66.79 | 69.30 | 63.72 | 66.58 | 55.02 | 69.45 | 70.59 | 76.02 |
| Operating Profit | 8.84 | 10.76 | 13.65 | 13.47 | 10.09 | 10.59 | 3.99 | 12.55 | 4.16 | 1.16 | 3.09 | 0.12 | 4.66 |
| OPM % | 13.40% | 19.66% | 22.45% | 22.51% | 15.38% | 13.69% | 5.44% | 16.45% | 5.88% | 2.06% | 4.26% | 0.17% | 5.78% |
| Other Income | -47.68 | 5.93 | 1.51 | -0.70 | -1.85 | -4.11 | 3.94 | -1.69 | -1.78 | 1.59 | 0.10 | 2.92 | -0.99 |
| Interest | 0.29 | 0.37 | 0.41 | 0.61 | 0.37 | 0.45 | 1.38 | 0.74 | 1.01 | 0.89 | 1.02 | 0.99 | 0.73 |
| Depreciation | 0.29 | 0.66 | 0.48 | 0.67 | 0.49 | 0.46 | 0.48 | 0.46 | 0.46 | 0.48 | 0.56 | 0.65 | 0.85 |
| Profit before tax | -39.42 | 15.66 | 14.27 | 11.49 | 7.38 | 5.57 | 6.07 | 9.66 | 0.91 | 1.38 | 1.61 | 1.40 | 2.09 |
| Tax % | 4.90% | 7.92% | 4.77% | 4.87% | 12.06% | 17.41% | 11.70% | 10.56% | 67.03% | 84.06% | 80.75% | 56.43% | 38.28% |
| Net Profit | -41.34 | 14.43 | 13.59 | 10.93 | 6.48 | 4.59 | 5.36 | 8.64 | 0.29 | 0.21 | 0.31 | 0.61 | 1.30 |
| EPS in Rs | -8.07 | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 46 | 231 | 279 | 336 | 241 | 293 | 270 | 280 |
| Sales growth | +236% | +407% | +21% | +20% | -28% | +21% | -8% | -6% | |
| Expenses | 12 | 37 | 189 | 229 | 279 | 197 | 254 | 261 | 271 |
| Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 38 | 10 | 9 |
| OPM % | 11% | 18% | 18% | 18% | 17% | 18% | 13% | 3.5% | 3.2% |
| Other Income | 1 | 1 | 2 | 5 | 3 | -38 | -4 | 3 | 4 |
| Interest | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 5 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 5 | 6 |
| Tax % | 19% | 31% | 14% | 13% | 19% | 219% | 13% | 73% | |
| Net Profit | 2 | 6 | 38 | 48 | 46 | -2 | 25 | 1 | 2 |
| EPS in Rs | 1.30 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 4.54 | 0.26 | 0.45 |
| Dividend Payout % | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -7.0% | 3.0% | – |
| Profit CAGR | -69.0% | -48.0% | – |
Shareholding Pattern
Promoters65.99%
FIIs3.50%
DIIs0.02%
Public30.49%
Promoters65.99%
FIIs1.74%
DIIs0.02%
Public32.24%
Promoters65.99%
DIIs2.56%
Public31.45%
Promoters65.99%
DIIs2.56%
Public31.45%
Promoters65.99%
DIIs2.56%
Public31.45%
Promoters71.57%
FIIs18.66%
DIIs0.03%
Public9.75%
Promoters66.86%
FIIs17.21%
DIIs0.02%
Public15.91%
Promoters65.99%
FIIs16.02%
DIIs0.02%
Public17.96%
Promoters65.99%
DIIs2.56%
Public31.45%
Promoters65.99%
DIIs2.56%
Public31.45%
BALAXI
Holdings Analysis
Key strengths & risk signals
52
Overall
46
Fundamental
58
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 41.8% in the last year.
BEARISH TREND! 50-day average (22.3) is below 200-day average (23.0) - negative signal.
LOWER HALF! Trading at 31.8% of 52W range - weakness visible.
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BREAKOUT! Stock has broken above resistance levels with momentum.
STRONG POSITION! Current price (23.4) is above both moving averages.
BELOW MARKET! Beta of 0.80 - slightly less volatile than market.
Fundamental & Technical Analysis
52Overall
46Fundamental
58Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -7.1% (DECLINING, 2/15). Profit CAGR: -68.6% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 0.9% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 10.18% public ownership - strong promoter/institutional control.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (22.3) is below 200-day average (23.0) - negative signal.
Price Position
8/10
STRONG POSITION! Current price (23.4) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
0/10
POOR YEAR! Stock declined 41.8% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 23,644 vs down days: 24,470. Ratio: 0.97x
RSI
3/5
NEUTRAL! RSI at 57.7 - balanced momentum.
52W Range
2/5
LOWER HALF! Trading at 31.8% of 52W range - weakness visible.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 6.7% (1 week), 5.7% (1 month), -2.3% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.80 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BALAXI | ₹23.40 | 52.1 | 0.9% | -7.1% | -68.6% | -41.8% | 52 | BREAKOUT | +333.3% | +116.7% | +14.1% | +14.1% |
| KREBSBIO | ₹59.20 | – | -49.7% | -23.1% | – | -13.3% | 54 | CONSOLIDATION | -11.5% | +116.0% | +38.1% | -17.1% |
| ALPA | ₹56.00 | 33.3 | 3.8% | 4.3% | 6.1% | -32.7% | 46 | CONSOLIDATING DOWN | -91.5% | -28.6% | +25.1% | -23.9% |
| BALPHARMA | ₹90.90 | 20 | 2.2% | 0.1% | 34.7% | +5.0% | 66 | CONSOLIDATING DOWN | +450.0% | -69.4% | +34.4% | +5.4% |
| PAR | ₹119.00 | 11.3 | 12.1% | 2.6% | 5.0% | +19.7% | 57 | BREAKDOWN | -36.6% | +188.9% | -4.5% | +39.8% |
| MEDICO | ₹18.40 | 11 | 5.8% | 11.0% | 38.0% | -64.4% | 55 | BREAKDOWN | -8.5% | -4.8% | +40.6% | +6.6% |
| NATCAPSUQ | ₹152.10 | – | -8.1% | 3.6% | – | -28.6% | 42 | CONSOLIDATING UP | +1.8% | +14.0% | +7.7% | -16.8% |
| VAISHALI | ₹7.10 | – | 4.1% | 18.0% | -15.2% | -26.9% | 49 | BREAKDOWN | – | +278.0% | – | -15.0% |
Data from TradeAlone · Updated daily
